Physician profile
Cody E Jarmon
NPI 1497230478
$2,462.20
in general payments reported to CMS, 2019-2025
32 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $769 · 2023: $737 · 2024: $395 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $384.88 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $308.49 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $296.77 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.95 | 2021-2024 | Relistor |
| Amgen INC. | $211.92 | 2021-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $90.76 | 2022-2023 | Verquvo, Belsomra, Lagevrio |
| Lilly USA, LLC | $84.02 | 2022-2024 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $75.57 | 2022-2025 | Spravato |
| Jazz Pharmaceuticals INC. | $70.36 | 2021-2022 | |
| Exact Sciences Corporation | $67.47 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $65.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.48 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.26 | 2021-2025 | |
| Daiichi Sankyo INC. | $42.20 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.29 | 2022-2024 | Breztri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $35.11 | 2023-2024 | |
| Harmony Biosciences LLC | $34.64 | 2023-2024 | Wakix |
| Corium, LLC | $28.99 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $23.85 | 2022 | |
| Dexcom, INC. | $23.85 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $20.35 | 2022 | |
| Pfizer INC. | $19.79 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.49 | 2022 | |
| Neurocrine Biosciences, INC. | $19.20 | 2023 | Ingrezza |
| Sumitomo Pharma America, INC. | $18.09 | 2024 | Gemtesa |
| Sun Pharmaceutical Industries INC. | $17.59 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.80 | 2022 | |
| Boston Scientific Corporation | $15.95 | 2025 | Watchman Access System |
| Sk Life Science, INC. | $15.63 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.00 | 2022 | |
| Lundbeck LLC | $14.31 | 2023 | Rexulti |
| Genentech USA, INC. | $1.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Jarmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.